NuVasive develops what it calls “minimally disruptive” surgical products and procedures for the spine, including applications for spine fusion surgery, including biologics. The company expanded in 2013, opening shop in Japan and buying its contract manufacturer, ANC LLC. Its product offering includes a surgical platform, Maximum Access Surgery, and an array of biologics, cervical and motion preservation products. The company’s spine surgery products include offerings for the thoracolumbar spine. NuVasive is also developing a set of motion-preservation products. Its biologics line includes allografts from donated human tissue; FormaGraft, a collagen synthetic product used to aid the fusion process; and Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.